Ampliphi Biosciences Corp (NYSEAMERICAN:APHB – Get Free Report) traded down 2.7% during mid-day trading on Tuesday . The stock traded as low as $2.14 and last traded at $2.14. 3,930 shares changed hands during trading, a decline of 100% from the average session volume of 842,200 shares. The stock had previously closed at $2.20.
Ampliphi Biosciences Stock Performance
Ampliphi Biosciences Company Profile
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P.
Further Reading
- Five stocks we like better than Ampliphi Biosciences
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- What is the S&P 500 and How It is Distinct from Other Indexes
- Netflix Is On Track To Hit $1,000 By Christmas
- The Significance of Brokerage Rankings in Stock Selection
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
